Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Advanced Solid TumorAdvanced/Metastatic Colorectal Cancer
Interventions
DRUG

Simmitecan

DRUG

5-fluorouracil and Leucovorin Calcium

DRUG

Thalidomide

Trial Locations (9)

50011

NOT_YET_RECRUITING

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

100000

RECRUITING

Beijing Cancer Hospital, Beijin

110001

NOT_YET_RECRUITING

The first hospital of China Medical University, Shenyang

200000

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

300060

NOT_YET_RECRUITING

Tianjin Cancer Hospital, Tianjin

410013

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

430030

NOT_YET_RECRUITING

Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan

Unknown

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

NOT_YET_RECRUITING

Jiangsu Cancer Hospital, Nanjing

Sponsors
All Listed Sponsors
lead

Haihe Biopharma Co., Ltd.

INDUSTRY